Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation

Elizabeth A. Griffiths, Steven D. Gore, Craig Hooker, Michael A. McDevitt, Judith E. Karp, B. Douglas Smith, Helai P. Mohammad, Ying Ye, James G. Herman, Hetty E. Carraway

Research output: Contribution to journalArticle

Abstract

Nuclear localization of non-phosphorylated, active β-catenin is a measure of Wnt pathway activation and is associated with adverse outcome in patients with acute myeloid leukemia (AML). While genetic alterations of the Wnt pathway are infrequent in AML, inhibitors of this pathway are silenced by promoter methylation in other malignanices. Leukemia cell lines were examined for Wnt pathway inhibitor methylation and total β-catenin levels, and had frequent methylation of Wnt inhibitors and upregulated β-catenin by Western blot and immunofluorescence. One hundred sixty-nine AML samples were examined for methylation of Wnt inhibitor genes. Diagnostic samples from 72 patients with normal cytogenetics who received standard high-dose induction chemotherapy were evaluated for associations between methylation and event-free or overall survival. Extensive methylation of Wnt pathway inhibitor genes was observed in cell lines, and 89% of primary AML samples had at least one methylated gene: DKK1 (16%), DKK3 (8%), RUNX3 (27%), sFRP1 (34%), sFRP2 (66%), sFRP4 (9%), sFRP5 (54%), SOX17 (29%), and WIF1 (32%). In contrast to epithelial tumors, methylation of APC (2%) and RASSF1A (0%) was rare. In patients with AML with normal cytogenetics, sFRP2 and sFRP5 methylation at the time of diagnosis was associated with an increased risk of relapse, and sFRP2 methylation was associated with an increased risk for death. In patients with AML: (a) there is a high frequency of Wnt pathway inhibitor methylation; (b) Wnt pathway inhibitor methylation is distinct from that observed in epithelial malignancies; and (c) methylation of sFRP2 and sFRP5 may predict adverse clinical outcome in patients with normal karyotype AML.

Original languageEnglish (US)
Pages (from-to)1711-1719
Number of pages9
JournalLeukemia and Lymphoma
Volume51
Issue number9
DOIs
StatePublished - Sep 1 2010

Keywords

  • Cytogenetics
  • DNA methylation
  • Wnt pathway
  • epigenetics
  • leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation'. Together they form a unique fingerprint.

  • Cite this

    Griffiths, E. A., Gore, S. D., Hooker, C., McDevitt, M. A., Karp, J. E., Smith, B. D., Mohammad, H. P., Ye, Y., Herman, J. G., & Carraway, H. E. (2010). Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leukemia and Lymphoma, 51(9), 1711-1719. https://doi.org/10.3109/10428194.2010.496505